Search
Home / About TransCon® Technology

Our Innovative Platform for Drug Development

TransCon technology combines the benefits of conventional prodrug and sustained release technologies to help solve the fundamental limitations seen in other approaches to extending duration of a drug’s action in the body. The TransCon name derives from transient conjugation, our unique ability to temporarily link an inert carrier to a parent drug with known biology to achieve sustained release.

About TransCon
About TransCon

TransCon Prodrugs Have Three Components

A parent drug with known biology
A known linker that temporarily binds the parent drug to an inert carrier
A known carrier that inactivates and shields the parent drug from clearance
The three components allow us to design TransCon prodrugs with predictable release of the unmodified parent drug to achieve the desired dosing frequency and pharmacological effect

TransCon

A flexible platform that can be applied to various types of parent drugs and that can be tailored to achieve different dosing and release profiles

Click to enlarge image

Sustained Systemic Release

When injected, physiological conditions initiate sustained release of the active, unmodified parent drug at a predictable rate

Click to enlarge image

References: 1. Thornton PS, et al. J Clin Endocrinol Metab. 2021;106(11):3184-3195. 2. Zúñiga LA, et al. Cancer Cell Int. 2022;22(1):286. 3. Breinholt VM, et al. Br J Clin Pharmacol. 2022;884:4763-4772. 4. Ascendis Pharma A/S. Form 20-F. Accessed May 28, 2025. SEC FILING | Ascendis Pharma.

Welcome to the Ascendis Pharma US Medical Website

This website is a self-service hub of scientific information, educational resources, and published clinical data related to Ascendis Pharma’s treatments and therapeutic areas of interest. This website is intended for healthcare professionals in the United States and its territories. By accessing and searching across this website, you confirm the unsolicited nature of your inquiry and interest. The website is made available by Ascendis Pharma’s US Medical Affairs organization and is provided as a resource for informational, non-promotional, and scientific exchange purposes only.

This website may contain information about products or uses that have not been approved by the U.S. Food and Drug Administration (FDA) and does not establish the safety or efficacy of these products or uses. There is no guarantee that investigational products and uses will receive FDA approval. The content of this site is not medical advice. Ascendis Pharma is unable to provide treatment recommendations outside of the approved product label. Treatment decisions should always be based on institutional standards and the treating healthcare professional’s clinical judgement based on the individual patient’s needs. Please review the full prescribing information for safety information and directions for use before prescribing medications. By selecting the option below, you acknowledge that you are a US healthcare professional.

Please report any adverse events related to any of our products by calling us at 1-844-442-7236.

You are encouraged to report side effects of prescription drugs to the FDA.
Call 1-800-FDA-1088 or visit www.fda.gov/medwatch.

I am a US HCP I am a US Patient or Caregiver I am not based in the US

You are now leaving the

Ascendis Pharma US Medical Website

You are now leaving the Ascendis Pharma US Medical Website. Third-party websites are not owned, endorsed, or controlled by Ascendis Pharma. Ascendis Pharma is not responsible for the content on third-party websites. Any opinions, claims, or comments expressed therein should not be attributed to Ascendis Pharma.

Stay on Ascendis Pharma US Medical Website Continue to third-party website

This site is not available

outside of the US

The site is intended only for healthcare professionals in the US.

CLOSE